Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | (37666486) | ||||||||||||
Authors | Lu S, Xie W, Zhang Y, Sun F, Huang J, Wang J, Zhu J, Zhen Z, Zhang Y | ||||||||||||
Title | Off-target Resistance to Larotrectinib in two Patients with NTRK Fusion-positive Pediatric Solid Tumors. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 - NTRK1 | infant-type hemispheric glioma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib) treatment resulted in an overall 65.8% size decrease in the enhancing lesions in a pediatric patient with infant-type hemispheric glioma harboring TP53-NTRK1 (PMID: 37666486). | 37666486 |